Press Releases

VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

By | Glioblastoma ("GBM"), Press Releases
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
Read More